Effect of UDCA on intestinal microecology in patients with non-obese fatty liver disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900028204

Enrollment

Unknown

Registered

2019-12-15

Start date

2020-01-01

Completion date

Unknown

Last updated

2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic steatohepatitis

Interventions

experimental group:UDCA treatment

control group:placebo

healthy group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: All NAFLD patients who met the diagnostic criteria for nonalcoholic fatty liver disease and were willing to undergo liver biopsy. However, there were 80 non-obese NAFLD patients (BMI<25kg/m^2) with elevated ALT, AST or GGT, and 40 non-nafld patients.

Exclusion criteria

Exclusion criteria: 1) suspected hepatocellular carcinoma; 2) complicated with viral hepatitis, drug-induced liver injury, autoimmune liver disease, primary biliary cirrhosis and hepatolenticular degeneration;Diseases such as chromopathy and - antitrypsin deficiency; 3) decompensated liver disease with one of the following indications: serum albumin 34.2 mol/L; 7) incomplete information.

Design outcomes

Primary

Measure	Time frame
glutamic-pyruvic transaminase;glutamic oxalacetic transaminase;gamma-glutamyltransferase;alkaline phosphatase;Intestinal flora sequencing;Bile acid spectrum;	—

Countries

China

Contacts

Public ContactJunping Shi

Affiliated Hospital of Hangzhou Normal University

20131004@hznu.edu.cn+86 13957121199

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026